Axi-cel CAR-T therapy extends EFS in patients with R/R large B-cell lymphoma
- The randomised phase 3 trial included 359 patients that were randomly assigned a single fusion of axi-cel or standard-of-care therapies for R/R large B-cell lymphoma
- Results showed a significant EFS improvement (HR = 0.39; P<0.0001) among patients assigned axi-cel
- Axi-cel also exhibited a safety profile consistent with that observed with use of the agent in the third-line setting
Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.